Brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) to report ($0.56) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Seres Therapeutics’ earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.61). Seres Therapeutics posted earnings of ($0.39) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 43.6%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Seres Therapeutics will report full-year earnings of ($2.05) per share for the current financial year, with EPS estimates ranging from ($2.59) to ($1.47). For the next year, analysts expect that the business will post earnings of ($1.16) per share, with EPS estimates ranging from ($2.86) to $0.29. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB – Get Rating) last announced its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The business had revenue of $7.22 million for the quarter, compared to analysts’ expectations of $19.48 million. Seres Therapeutics had a negative net margin of 45.25% and a negative return on equity of 47.52%. During the same quarter in the prior year, the company posted ($0.18) earnings per share.
Shares of NASDAQ MCRB traded down $0.50 during mid-day trading on Monday, hitting $6.08. 553,459 shares of the company’s stock traded hands, compared to its average volume of 645,331. The company’s 50-day moving average is $7.37 and its two-hundred day moving average is $7.75. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.19. Seres Therapeutics has a 1 year low of $5.41 and a 1 year high of $25.06.
A number of large investors have recently modified their holdings of the stock. Two Sigma Investments LP grew its stake in Seres Therapeutics by 527.8% in the 3rd quarter. Two Sigma Investments LP now owns 999,416 shares of the biotechnology company’s stock worth $6,956,000 after acquiring an additional 840,214 shares in the last quarter. HAP Trading LLC bought a new position in Seres Therapeutics in the 3rd quarter worth about $279,000. Janney Montgomery Scott LLC bought a new position in Seres Therapeutics in the 3rd quarter worth about $186,000. Cubist Systematic Strategies LLC grew its stake in Seres Therapeutics by 1,049.1% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 318,190 shares of the biotechnology company’s stock worth $2,215,000 after acquiring an additional 290,499 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in Seres Therapeutics in the 3rd quarter worth about $3,271,000. Institutional investors own 80.53% of the company’s stock.
About Seres Therapeutics (Get Rating)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.